摘要
目的监测并分析我院贝伐珠单抗不良反应(Adverse reactions,ADR),促进患者用药安全。方法临床药师主动监测2022年1月1日~2023年8月31日在我院使用贝伐珠单抗治疗且发生ADR的173例肿瘤患者,分析患者ADR发生情况及特点。结果83名患者中,男48例(57.83%),女35例(42.17%);65~74岁的患者占53.01%;ADR表现主要在血液系统和胃肠道系统,其中白细胞降低(15.03%)、骨髓抑制(16.76%)、胃肠道反应(16.76%)和高血压(7.51%)发生率较高;ADR发生时间多在30d以内(83.82%);治疗方案中,合并两种药物(66.47%)最多;130例经治疗后好转。结论临床应加强药品ADR监测力度,提高用药合理性和安全性,减少ADR发生。
OBJECTIVE The Adverse reactions(ADR)of bevacizumab in our hospital were monitored and analyzed to promote the safety of medication.METHODS Clinical pharmacists actively monitored 173 cancer patients who were treated with bevacizumab and developed ADR in our hospital from January 1,2022 to August 31,2023,and analyzed the occurrence and characteristics of ADR.RESULTS Among the 83 patients,48 were males(57.83%)and 35 were females(42.17%).53.01% of patients aged 65-74 years;ADR mainly occurred in the blood system and gastrointestinal system,among which the incidence of leukopenia(15.03%),bone marrow suppression(16.76%),gastrointestinal reaction(16.76%)and hypertension(7.51%)were higher.ADR occurred within 30 days(83.82%).The combination of two drugs(66.47%)was the most common treatment regimen.130 cases improved after treatment.CONCLUSION Clinical monitoring of drug ADR should be strengthened to improve the rationality and safety of drug use and reduce the occurrence of ADR.
作者
李素素
马曾庆
张红
史红军
吴连平
LI Su-su;MA Zeng-qing;ZHANG Hong;SHI Hong-jun;WU Lian-ping(Department of Pharmacy,Nanjing Gaochun People's Hospital,Nanjing 211300,China)
出处
《海峡药学》
2024年第8期102-105,共4页
Strait Pharmaceutical Journal
基金
江苏大学医教协同创新基金项目,项目编号(JDYY2023026)。
关键词
药品不良反应
贝伐珠单抗
合理用药
药学监护
Adverse drug reactions
Bevacizumab
Rational drug use
Pharmaceutical care
